Glaucoma, capillaries and pericytes. 3. Peptide hormone binding and influence on pericytes.
To test the potential for vasoactive neuropeptide receptors to affect capillary resistance, we have begun to study the plausibility that pericytes might be equipped to respond to a representative peptide vasoconstrictor and a representative peptide vasodilator. Pericytes cultured from the bovine retinal vasculature specifically bind the angiotensin II (Ang II) antagonist saralasin (1 nM125I-saralasin bound at 2.2 +/- 0.41 fmol/mg protein) and 125I-vasoactive intestinal peptide (VIP; Kd of 0.5 nM with a population of 30 fmol/mg protein). Incubation with 100 microM Ang II induced minimal cAMP synthesis, while VIP (1 microM, 10 microM) did not induce any change in cAMP concentration. Ang II (10 microM and 100 microM) caused contraction of pericytes cultured on an elastic silicone surface. Circulating or locally produced vasoactive neuropeptides might affect pericyte contractile tone via several intracellular pathways, moderated by indirect effects of these peptides through endothelial stimulation, with the net effect on local blood flow resulting from the effects on arteries and veins as well as capillaries.
Ferrari-Dileo
G
G
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Fla., USA.
Davis
E B
EB
Anderson
D R
DR
D000804:Angiotensin II / Q000378:metabolism / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites; D001783:Blood Flow Velocity; D002196:Capillaries / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D002200:Capillary Resistance; D002417:Cattle; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000096:biosynthesis; D005901:Glaucoma / Q000503:physiopathology*; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000378:metabolism; D009900:Optic Nerve / Q000098:blood supply; D012171:Retinal Vessels / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D012504:Saralasin / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism* / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000378:metabolism / Q000494:pharmacology
D000806:Angiotensin-Converting Enzyme Inhibitors; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D014660:Vasoactive Intestinal Peptide; D000242:Cyclic AMP; D012504:Saralasin